Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pedro Sevilla Saez Benito

Pulmonary Disease Miami, FL Medical Doctor

NPI 1902071939 CMS profile 358196

7000 Sw 97Th Ave Ste 120, Miami, FL 33173

Open in the dashboard

General payments

$23,262

862 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pedro Sevilla Saez Benito of Miami, FL is reported in the CMS Open Payments database as having received $23,262 across 862 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,256 127
2024 General $2,791 112
2023 General $4,381 161
2022 General $3,773 153
2021 General $3,546 144
2020 General $1,423 64
2019 General $4,093 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pedro Sevilla Saez Benito
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Pedro Sevilla Saez Benito were reported at $3,256. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Pedro Sevilla Saez Benito Pulmonary Disease median Middle half National median
2019 $4,093 $377 $109–$1,340 $163
2020 $1,423 $230 $56–$907 $114
2021 $3,546 $269 $68–$1,072 $132
2022 $3,773 $390 $100–$1,457 $149
2023 $4,381 $419 $114–$1,659 $160
2024 $2,791 $476 $123–$1,818 $164
2025 $3,256 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $5,072 166 payments
  2. AstraZeneca Pharmaceuticals LP $2,001 96 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,804 84 payments
  4. Actelion Pharmaceuticals US, Inc. $1,424 63 payments
  5. Ethicon Inc. $1,362 8 payments
  6. Genzyme Corporation $1,117 39 payments
  7. Insmed, Inc. $924 39 payments
  8. United Therapeutics Corporation $833 25 payments
  9. Regeneron Healthcare Solutions, Inc. $832 39 payments
  10. Pulmonx Corporation $821 3 payments
  11. Other $7,073 300 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $21,233 849 payments
  2. Travel and Lodging $1,746 5 payments
  3. Education $283 8 payments
Products named General payments · program years 2019–2025
  1. NUCALA $2,139 71 payments
  2. TRELEGY ELLIPTA $2,116 75 payments
  3. UPTRAVI $1,390 61 payments
  4. DUPIXENT Immunology $1,302 40 payments
  5. OPSUMIT $1,064 47 payments
  6. Monarch $967 3 payments
  7. Arikayce $906 38 payments
  8. Pulmonx Endobronchial Valve EBV $821 3 payments
  9. DUPIXENT Inflammation And Immunology $744 35 payments
  10. ACTHAR $689 28 payments
  11. Other $12,987 560 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

3,631

Median for Pulmonary Disease: 936

Drug cost

$2,364,291

Median for Pulmonary Disease: $487,987

Branded share of claims

72%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 53 $694,553
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 663 $475,527
Nucala Mepolizumab Brand 103 $391,129
Breo Ellipta Fluticasone/Vilanterol Brand 432 $188,940
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 183 $118,933
Dupixent Pen Dupilumab Brand 30 $115,765
Tezspire Tezepelumab-Ekko Brand 15 $65,693
Spiriva Respimat Tiotropium Bromide Brand 83 $46,689
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 75 $41,456
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 58 $33,370

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$226,347

Medicare's payments for the services billed

Medicare patients

711

Average age 77

Services billed

3,009

424 women, 287 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 59%
Arthritis 59%
COPD 56%
Diabetes 47%
Heart failure 40%
Chronic kidney disease 40%
Atrial fibrillation 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
$398 103 —
OFEV
$265 53 —
DUPIXENT
$244 30 —
TRELEGY ELLIPTA
$234 663 —
Arikayce
$195 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

862 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record